Neurocrine Biosciences (NBIX) Jefferies 2024 Global Healthcare Conference summary

Leadership transition and succession planning

• CEO retiring after 32 years, with a smooth transition planned to a long-standing internal successor.

• Succession discussions began six years ago, with COVID delaying the timeline.

• Outgoing CEO will remain on the board to support continuity.

• Successor will conduct a company-wide listening tour over several months.

Strategic outlook and financial guidance

• Company evolving from a single-product to a multi-product portfolio, with up to four products expected in coming years.

• No commitment to five-year long-term guidance due to market and regulatory uncertainties, including IRA and potential political changes.

• Financial position described as strong, with significant EBITDA potential from existing products.

Muscarinic franchise and clinical development

• Muscarinic program (notably 568) features high selectivity for M4, with a clean preclinical tox profile and no significant GI side effects observed.

• Cardiovascular signals are monitored, but no concerning effects seen to date; safety board focuses solely on safety for dose escalation.

• Adaptive trial design used for phase II, primarily to ensure safety before dose escalation.

• Data from phase II will inform dosing and potential expansion into Alzheimer's psychosis, with schizophrenia as the primary registration focus.

• Efficacy benchmark for success is a placebo-corrected PANSS benefit above 8, with good safety and tolerability.